Evidence map›Paper›PMID 21791217›Full record

ArticleJournal of molecular and cellular cardiology2011

Endothelial-cardiomyocyte crosstalk enhances pharmacological cardioprotection.

Thorsten M Leucker, Martin Bienengraeber, Maria Muravyeva, Ines Baotic, Dorothee Weihrauch, Anna K Brzezinska, David C Warltier, Judy R Kersten, Phillip F Pratt

Open access · greenAbstract read
In one paragraph

Article in Journal of molecular and cellular cardiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Endothelial cell dysfunction in cardiac disease: driver or consequence?Frontiers in cell and developmental biology · 2023
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Thorsten M LeuckerDepartment of Anesthesiology Medical College of Wisconsin, Milwaukee, WI, USA.
Martin Bienengraeber
Maria Muravyeva
Ines Baotic
Dorothee Weihrauch
Anna K Brzezinska
David C Warltier
Judy R Kersten
Phillip F Pratt
Medical College of Wisconsin · US

Funding

Stem Cell CoreP01GM066730 · NIGMS · MEDICAL COLLEGE OF WISCONSIN · PI BOSNJAK, ZELJKO J. · 2003 to 2019
$23.6M
Effects of Anesthetics on Ischemic MyocardiumR01HL054820 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI WARLTIER, DAVID C. · 1995 to 2007
$3.1M
MECHANISMS OF MYOCARDIAL ISCHEMIC INJURY IN DIABETESR01HL063705 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI KERSTEN, JUDY R. · 2001 to 2010
$3.0M
Mechanisms of photobiomodulation in myocardial reperfusion injuryR01HL098490 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI BIENENGRAEBER, MARTIN · 2010 to 2013
$1.5M
NHLBI NIH HHS HL 054820NHLBI NIH HHS HL 066730NHLBI NIH HHS R01 HL054820NHLBI NIH HHS R01 HL063705NHLBI NIH HHS R01 HL098490NIGMS NIH HHS GM 066730NIGMS NIH HHS P01 GM066730
6 · The paper itself

Abstract

Endothelial cells (EC) serve a paracrine function to enhance signaling in cardiomyocytes (CM), and conversely, CM secrete factors that impact EC function. Understanding how EC interact with CM may be critically important in the context of ischemia-reperfusion injury, where EC might promote CM survival. We used isoflurane as a pharmacological stimulus to enhance EC protection of CM against hypoxia and reoxygenation injury. Triggering of intracellular signal transduction pathways culminating in the enhanced production of nitric oxide (NO) appears to be a central component of pharmacologically induced cardioprotection. Although the endothelium is well recognized as a regulator for vascular tone, little attention has been given to its potential importance in mediating cardioprotection. In the current investigation, EC-CM in co-culture were used to test the hypothesis that EC contribute to isoflurane-enhanced protection of CM against hypoxia and reoxygenation injury and that this protection depends on hypoxia-inducible factor (HIF1α) and NO. CM were protected against cell injury [lactate dehydrogenase (LDH) release] to a greater extent in the presence vs. absence of isoflurane-stimulated EC (1.7 ± 0.2 vs. 4.58 ± 0.8 fold change LDH release), and this protection was NO-dependent. Isoflurane enhanced release of NO in EC (1103 ± 58 vs. 702 ± 92 pmol/mg protein) and EC-CM in co-culture sustained NO release during reoxygenation. In contrast, lentiviral mediated HIF1α knockdown in EC decreased basal and isoflurane stimulated NO release in an eNOS dependent manner (517 ± 32 vs. 493 ± 38 pmol/mg protein) and prevented the sustained increase in NO during reoxygenation when co-cultured. Opening of mitochondrial permeability transition pore (mPTP), an index of mitochondrial integrity, was delayed in the presence vs. absence of EC (141 ± 2 vs. 128 ± 2.5 arbitrary mPTP opening time). Isoflurane stimulated an increase in HIF1α in EC but not in CM under normal oxygen tension (3.5 ± 0.1 vs. 0.79 ± 0.15 fold change density) and this action was blocked by pretreatment with the Mitogen-activated Protein/Extracellular Signal-regulated Kinase inhibitor U0126. Expression and nuclear translocation of HIF1α were confirmed by Western blot and immunofluorescence. Taken together, these data support the concept that EC are stimulated by isoflurane to produce important cardioprotective factors that may contribute to protection of myocardium during ischemia and reperfusion injury.

Indexed as

Signal TransductionAnimalsButadienesCell SurvivalCoculture TechniquesEndothelial CellsEndothelium, VascularEnzyme InhibitorsFemaleHumansHypoxiaHypoxia-Inducible Factor 1, alpha SubunitIsofluraneL-Lactate DehydrogenaseMitochondrial Membrane Transport ProteinsMitochondrial Permeability Transition PoreButadienesEnzyme InhibitorsHIF1A protein, humanHypoxia-Inducible Factor 1, alpha SubunitIsofluraneL-Lactate DehydrogenaseMitochondrial Membrane Transport ProteinsMitochondrial Permeability Transition PoreNitric OxideNitric Oxide Synthase Type IIINitrilesNOS3 protein, humanU 0126

Identifiers

PMID21791217
PMCPMC3342532
OpenAlexW2008872843

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.